ArticleRetina (Philadelphia, Pa.)2026
EPIRETINAL MACROPHAGE-LIKE CELL ALTERATIONS FOLLOWING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN BRANCH RETINAL VEIN OCCLUSION WITH MACULAR EDEMA: A Retrospective Longitudinal Study.
Article in Retina (Philadelphia, Pa.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo investigate the impact of anti-vascular endothelial growth factor therapy on epiretinal macrophage-like cells (eMLC) in branch retinal vein occlusion with macular edema (BRVO-ME) patients.
methodsThis retrospective study included 58 BRVO-ME patients treated with anti-vascular endothelial growth factor agents, divided into 2 groups: 28 eyes (1-2 Injection group) and 30 eyes (3 Injection group). The 3-injection group comprised 20 early responders and 10 limited early responders (LERs). Longitudinal changes in macular eMLC count and density were assessed through en face optical coherence tomography during the early response phase (baseline to 3 months postinitial injection). Linear regression and Spearman correlation analyzed eMLC density's relationship with optical coherence tomography angiography parameters and systemic inflammatory indices.
resultsThe 3-injection group exhibited greater reductions in macular edema and eMLC density than the 1 to 2 injection group. Macular eMLC density significantly decreased in early responders, whereas LERs showed no significant alteration. Posttreatment central macular thickness change positively correlated with eMLC density change (r = 0.57). Baseline systemic inflammatory indices (neutrophil/lymphocyte ratio, r = -0.46; neutrophil/platelet ratio, r = -0.36; systemic immune-inflammation index, r = -0.33; systemic inflammatory response index, r = -0.31) negatively correlated with posttreatment eMLC density change.
conclusionAnti-vascular endothelial growth factor therapy reduces macular eMLC in BRVO-ME patients, especially in early responders receiving three injections. Macular eMLCs are closely associated with inflammation and may serve as a valuable treatment response biomarker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.